Strides Up 12% on FDA Approval, Portfolio Gains


This is a Capital Mind Premium post, sent on April 26, 2014.

Strides Arcolab has seen a surge in its stock price on news that the FDA continues its approvalfor Strides’ Bangalore oral dosage facility. It has gone up 12 to Rs. 526.

The rest of this content is only available to premium members.

Already a subscriber? Log in now!

Register for a premium membership today! Apart from this content you will get our proprietary research and weekly newsletter too!

Get Your Capital Mind Premium Subscription

Get Capitalmind Premium